Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482473 | 0.73 | ABCB1 (0.40) | BRD4ABCB1 | |
| SCHEMBL482786 | 0.67 | PTGDR2 (0.42) | BRD4 | |
| SCHEMBL19096767 | 0.64 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL16722028 | 0.62 | BRD4 (0.65) | BRD4 | |
| SCHEMBL16722026 | 0.62 | BRD4 (0.65) | BRD4 | |
| SCHEMBL16062109 | 0.59 | CETP (0.31) | — | |
| SCHEMBL16062110 | 0.59 | CETP (0.31) | — | |
| SCHEMBL21172472 | 0.57 | NNMT (0.38) | — | |
| SCHEMBL2222843 | 0.57 | PSEN1 (0.35) | ALDH1A1 | |
| SCHEMBL21141895 | 0.56 | BRD4 (0.43) | BRD4ABCB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | BRD4 1271/4885ABCB1 2175/4885CA1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.